Riviciclib

N/A

Report date: 2023/05/05 17:38:38
NME

Base Information

Drug NameRiviciclib
Drug Alias NameRiviciclibum利威西利利维西利P-276P-276-00
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 9 inhibitorsCyclin-dependent kinase 4 inhibitors
TargetsCyclin-dependent kinase 4Cyclin-dependent kinase 9
Therapy Area/IndicationsMucositisHead and Neck NeoplasmsPancreatic Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNew Zealand +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPiramal Phytocare
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPiramal PhytocarePiramal Enterprises Ltd
Active IndicationsN/A
Inactive IndicationsMucositisHead and Neck NeoplasmsPancreatic Neoplasms +[9] 

Other Information

ATC CodeN/A
Related LinksN/A